German Health Authority Denies Additional Benefit for Alzheimer Drug Donanemab

The Federal Joint Committee (G-BA) in Germany has concluded that the Alzheimer’s drug Donanemab, marketed as Kisunla, offers no demonstrated added benefit compared to existing standard therapeutic options. This decision, based on a utility assessment by the Institute for Quality and Efficiency in Health Care (IQWiG), establishes the framework for upcoming price negotiations between the manufacturer and statutory health insurance providers.

Donanemab is indicated for patients with early-stage Alzheimer’s disease and confirmed amyloid pathology. However, the evaluation found that clinical trial data failed to show statistically significant differences in outcomes compared to patients receiving standard acetylcholinesterase inhibitors. Experts note that the difficulty in measuring efficacy at such an early stage of the disease remains a major hurdle for regulatory approval and assessment.

Alzheimer Forschung Initiative (AFI) stated that while the decision does not restrict physicians from prescribing the medication, it marks a critical milestone in the debate over the cost-effectiveness and clinical evidence of monoclonal antibody therapies. The outlook for patient access now rests on the outcomes of the impending price negotiations.